Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of Ubrogepant with Erenumab or Galcanezumab in Migraine
NCT04179474Phase 1Completed
- Sponsor
- Allergan
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ubrogepant in migraine (2 arms), sponsored by Allergan. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t at Day 12, Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity at Day 12 and 1 more. Started Sep 2019; status: completed.
02
Drugs
ubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04179474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179474.